FY2026 Earnings Estimate for X4 Pharmaceuticals, Inc. Issued By Oppenheimer (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFORGet Rating) – Research analysts at Oppenheimer issued their FY2026 EPS estimates for X4 Pharmaceuticals in a report released on Thursday, May 12th. Oppenheimer analyst L. Gershell expects that the company will earn $1.05 per share for the year.

Several other analysts have also weighed in on XFOR. Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $19.00 to $10.00 in a report on Thursday, March 17th. Canaccord Genuity Group cut their price objective on X4 Pharmaceuticals from $20.00 to $10.00 in a report on Tuesday, April 5th. HC Wainwright cut their price objective on X4 Pharmaceuticals from $11.00 to $8.50 in a report on Friday. Zacks Investment Research lowered X4 Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 17th. Finally, Canaccord Genuity Group cut their target price on X4 Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th.

Shares of XFOR stock opened at $1.20 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 6.27 and a current ratio of 6.27. The firm has a market capitalization of $36.99 million, a PE ratio of -0.35 and a beta of 0.62. The stock has a fifty day moving average of $1.60 and a two-hundred day moving average of $2.42. X4 Pharmaceuticals has a 1 year low of $1.00 and a 1 year high of $9.90.

X4 Pharmaceuticals (NASDAQ:XFORGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.10). During the same period in the prior year, the business posted ($1.30) earnings per share.

A number of large investors have recently made changes to their positions in XFOR. BlackRock Inc. raised its holdings in X4 Pharmaceuticals by 2.0% in the 3rd quarter. BlackRock Inc. now owns 268,450 shares of the company’s stock valued at $1,419,000 after acquiring an additional 5,160 shares in the last quarter. Morgan Stanley raised its holdings in X4 Pharmaceuticals by 227.8% in the 2nd quarter. Morgan Stanley now owns 10,242 shares of the company’s stock valued at $67,000 after acquiring an additional 7,118 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in X4 Pharmaceuticals by 100.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 20,949 shares of the company’s stock valued at $48,000 after acquiring an additional 10,474 shares in the last quarter. Marshall Wace LLP raised its holdings in X4 Pharmaceuticals by 84.0% in the 3rd quarter. Marshall Wace LLP now owns 25,223 shares of the company’s stock valued at $133,000 after acquiring an additional 11,514 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 76.63% of the company’s stock.

X4 Pharmaceuticals Company Profile (Get Rating)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Recommended Stories

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.